v3.26.1
COLLABORATIONS - Schedule of Revenue Recognized under Collaboration (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue Recognized $ 1,290,948 $ 773,689 $ 2,458,123 $ 1,367,878
Regeneron Pharmaceuticals        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue Recognized 5,020 32,542 51,356 83,581
Regeneron Pharmaceuticals | Research Services Obligation | Global Strategic Collaboration        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue Recognized (802) 12,957 5,831 26,767
Regeneron Pharmaceuticals | C5 License Obligation | Global Strategic Collaboration        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue Recognized 0 0 0 21,458
Regeneron Pharmaceuticals | Regeneron Technology Transfer Obligation | Global Strategic Collaboration        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue Recognized 0 0 0 2,431
Regeneron Pharmaceuticals | Other license programs | Global Strategic Collaboration        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue Recognized $ 5,822 $ 19,585 $ 45,525 $ 32,925